James L. Mohler, MD, discusses the evolving role of genetic testing in patients with prostate cancer following the updates to the National Cancer Care Network Guidelines, which now include guidance for better practice in terms of conducting genetic testing in this patient population.
James L. Mohler, MD, associate director and senior vice president for translational research, and professor of oncology, Roswell Park Comprehensive Cancer Center, discusses the evolving role of genetic testing in patients with prostate cancer following the updates to the National Cancer Care Network (NCCN) Guidelines, which now include guidance for better practice in terms of conducting genetic testing in this patient population.
The importance of genetic testing has been recognized, says Mohler, but there is a deficient in the number of highly trained and qualified genetic counselors. Although physicians are functioning well despite these odds, certificate programs are available that provide more individuals with short courses to improve on their knowledge of genetic testing so that physicians can do a better job at pre-genetic testing counseling.
As a urologist, Mohler says that he lacks in this area of expertise as well, which is why more genetic counselors need to be trained.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
Successes With T-DXd and the Need for Continued Research in Brain Metastasis
June 13th 2024In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.
Read More